**Author details**

Jordi Botet GMP Consultant, Barcelona, Spain

\*Address all correspondence to: jbotetfregola@gmail.com

© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**167**

*Pharmaceutical Projects: Walking along the Risk Management Line*

http: //ec.europa.eu/health/documents/

[9] US National Archives & Records Administration: Federal Register. Code of Federal Regulations (CFR). Title 21 (Food & drugs). Parts 210 through 226.

[10] WHO. Good manufacturing practices

for biological products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-Third Report (WHO Technical Report Series, No. 996). Annex 3. Geneva,

[11] U.S. Department of Health and Human Services. Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination. Guidance for Industry. Current Good Manufacturing Practices (CGMPs). Rockville, MD, USA: Food and Drug Administration (FDA). Center for Drug Evaluation and Research

[12] EMA (European Medicines Agency). CHMP (Committee for Medicinal Products for Human Use), CVMP (Committee for Medicinal Products for Veterinary Use). Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities. EMA/ CHMP/CVMP/SWP/169430/2012.

[13] WHO. Good manufacturing practices for pharmaceutical products containing hazardous substances. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-Fourth Report (WHO Technical Report Series, No. 957). Annex 3. Geneva,

[14] US Department of Health and Human Services. Biosafety in Microbiology

eudralex/vol-4\_en

https: //www.govinfo.gov

Switzerland: WHO; 2016

(CDER); 2013

London: EMA; 2014

Switzerland: WHO; 2010

*DOI: http://dx.doi.org/10.5772/intechopen.82601*

[2] ICH. Pharmaceutical Development. Harmonised Guideline Q8(R2). Geneva,

[3] ICH. Quality Risk Management. Harmonised Guideline Q9. Geneva,

Biotechnological/Biological Entities). Harmonised Guideline Q11. Geneva,

[6] WHO (World Health Organisation). Guidelines on quality risk management.

In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-Seventh Report (WHO Technical Report Series, No. 981). Annex 2. Geneva, Switzerland:

[7] WHO. Good manufacturing practices for pharmaceutical products: Main principles. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-Eighth Report (WHO Technical Report Series, No. 986). Annex 2. Geneva,

Switzerland: WHO; 2014

[8] European Commission. Good Manufacturing Practices. Medicinal Products for Human and Veterinary Use. The Rules Governing Medicinal Products in the European Union. Vol. 4. Brussels.

WHO; 2013

[5] ICH. Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. Harmonised Guideline Q12, Draft. Geneva, Switzerland: ICH; 2017

[1] ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). Pharmaceutical Quality System. Harmonised Guideline Q10. Geneva, Switzerland: ICH; 2008

**References**

Switzerland: ICH; 2009

Switzerland: ICH; 2005

(Chemical Entities and

Switzerland: ICH; 2012

[4] ICH. Development and Manufacture of Drug Substances *Pharmaceutical Projects: Walking along the Risk Management Line DOI: http://dx.doi.org/10.5772/intechopen.82601*
